NCT07342699Completed
Location-Molecular Integrated Outcomes in 450 Cerebellar Glioma Microsurgical Cases
Microsurgical Outcomes and Prognostic Analysis of 450 Cases of Cerebellar Gliomas: Integrating Pathology, Molecular Biomarkers, and Novel Clinical Insights
Source: ClinicalTrials.gov · Last updated 15 Jan 2026
Brief summary (registry, in English)
The goal of this observational study is to learn if refined anatomical location-combined with molecular biomarkers-can predict surgical success and long-term survival in 450 adults and children with cerebellar gliomas who underwent microsurgical resection at a single center between 2014 and 2024. The main questions it aims to answer are: 1. Does tumor location (cerebellar hemisphere, vermis, fourth ventricle, or pontocerebellar-angle region) independently influence extent of resection and overall survival after adjustment for WHO grade and molecular profile? 2. Among IDH-wild-type low-grade gliomas, does gross-total resection plus early adjuvant radiotherapy improve 5-year overall and progression-free survival compared with lesser resection or radiotherapy omission? Researchers compared four anatomical subgroups and multiple molecular subtypes (IDH, 1p/19q, MGMT, TERT, BRAF V600E) to quantify location-specific resection rates, complication rates, and survival outcomes. Participants underwent standardized pre-operative imaging, microsurgical resection with intra-operative monitoring when indicated, post-operative MRI within 48 h to quantify residual tumor, and longitudinal clinical and radiographic follow-up every 3-12 months for up to 10 years.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 450 (actual)
- First submitted
- 25 Dec 2025
- Start date
- 1 Jan 2014
- Primary completion date
- 1 Jan 2024
- Lead sponsor
- West China Hospital
- Diseases
- Childhood cancers
- NCT number
- NCT07342699
What you commit to
- Study type: Observational
- Participants enrolled: 450
- From 1 Jan 2014 to the primary completion date, 1 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous cranial radiation or glioma surgery at another institution
- Palliative resection (\< 20 % of tumor volume removed)
Other
- Brain-stem glioma with secondary cerebellar invasion
- Recurrent or metastatic glioma
- Missing post-operative MRI or insufficient tissue for mandatory IDH testing
- Follow-up \< 6 months or lost to follow-up before 6-month landmark
Who the study is looking for
- Pathologically proven cerebellar glioma (hemisphere, vermis, fourth ventricle, or pontocerebellar-angle region) per 2021 WHO CNS classification
- First microsurgical resection performed at our center between January 2014 and January 2024
- Age ≥ 3 years at surgery
- Pre-operative Karnofsky Performance Status (KPS) recorded
- Availability of post-operative contrast MRI for resection-extent calculation
- Minimum required molecular data: IDH1/2 status (immunohistochemistry ± sequencing)
- Continuous follow-up ≥ 6 months after surgery (out-patient visits or telephone confirmation)
Age in the registry: 3 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| West China Hospital of Sichuan University Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.